◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound OPTIONAL-ADD HIGH

Vitamin C

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict OPTIONAL-ADD HIGH

"Cheap, safe, broadly useful — but marginal benefit of supplementation in a young athlete with a varied diet is modest. Mainly worthwhile for: heavy training and sickness windows (immune support), pre/peri-workout (iron co-absorption with non-heme sources), connective-tissue recovery (collagen synthesis after injury). Don't mega-dose chronically — controversial evidence that very high doses may blunt training adaptations."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, MMA athlete + business owner (Dylan's archetype)
    OPTIONAL-ADD

    Two genuine non-redundant use cases: (1) Shaw 500 mg + 15 g collagen pre-rehab/training for tendon/ligament reinforcement (the strongest evidence-based athletic vit C application — directly relevant to MMA joint load and to his existing collagen peptides line); (2) 200-500 mg/d during MMA camps + cold-weather training windows — Hemilä's 50% URTI risk reduction in athletes is meaningful at his training load. Outside those, food sources (citrus, peppers, kiwi, broccoli) reliably cover the RDA. Action: add 250-500 mg ascorbic acid tabs to V4 daily; use Shaw protocol on heavy joint-loading days; bump to 500 mg twice daily during illness exposure or camps.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same logic without the tendon-loading priority. 200-500 mg/d covers immune resilience during travel/illness exposure. Whole-food intake should cover most needs.

  • 50+, aging adult, mild cognitive decline focus
    POSSIBLE

    Some signal for CV/endothelial benefit at 500 mg/d. Cataract prevention dietary signal. No compelling cognitive benefit signal — vitamin C is not a nootropic in vitamin-replete subjects. Watch kidney stone history (incidence rises with age).

  • URTI prevention in cold-climate athlete / military / endurance athlete (Hemilä cohort)
    PRIMARY-PICK

    0.2-1 g/d during exposure window; ~50% incidence reduction. This is the strongest use case for vitamin C in the literature.

  • Pregnancy / postpartum
    OPTIONAL-ADD

    RDA +20 mg/d (110 mg/d total). Higher doses safe but not advantageous.

  • Smoker
    STRONG-CANDIDATE

    Smokers have ~30-40% lower plasma ascorbate at any intake; RDA +35 mg/d. Functional intake target ~120-200 mg/d.

  • Plant-based / vegan athlete
    STRONG-CANDIDATE

    for iron co-absorption. 100 mg with iron-containing meals doubles fractional absorption.

  • Anxiety-prone / mood-focused
    NEUTRAL

    Some marginal stress-response support via adrenal ascorbate maintenance, but not a clinically meaningful anxiolytic. Skip the "vit C for stress" framing.

  • Kidney stone history (calcium oxalate)
    CAUTION

    Cap at 500 mg/d; ensure 2-3 L/day fluid intake. Avoid megadosing.

  • Hemochromatosis (HFE C282Y or H63D)
    CAUTION

    Limit to ≤100 mg/d; never co-administer with iron-containing meals. Avoid IV megadose.

  • G6PD deficiency
    CAUTION

    for IV megadose; oral safe. Up to 1-2 g/d oral generally tolerated; avoid IV >7.5 g.

  • Active chemotherapy
    CAUTION

    Coordinate with oncology — antioxidant interaction with some chemotherapy agents.

  • Sepsis (in-hospital)
    SKIP

    based on LOVIT 2022 mortality signal in IV vit C arm.

  • Endurance athlete in active VO2max-adaptation phase
    MODERATE CAUTION

    Keep chronic dose ≤200 mg/d; avoid peri-workout dosing of 1+ g; preserve mitohormesis signal.

▸ Subjective experience (deep)

Vitamin C at supplementation doses (100 mg-1 g) has no perceptible acute subjective effect in vitamin-replete individuals. Users sometimes describe "feeling a bit better" within hours of dosing 1+ g during a cold — this is plausibly real (immune-cell concentration rebound) but slow enough that the conscious read is unreliable.

At doses ≥2 g, the only reliable subjective signals are GI: bloating, loose stools, frank osmotic diarrhea ("bowel tolerance" — a folk metric advocated by Klenner/Cathcart for finding individual ceiling). Time-release and buffered (calcium/sodium ascorbate) preparations push tolerance higher.

At megadoses (5-10 g IV or high oral with bowel tolerance), some users report mild warmth, transient blood pressure changes, occasional headache — not consistent enough to dose around.

For Dylan's archetype: treat vitamin C as a non-experiential utility supplement. The cognitive/mood effects sometimes reported are almost certainly placebo unless he was actually low at baseline.

▸ Tolerance + cycling deep dive
  • No pharmacodynamic tolerance — receptor downregulation doesn't apply (no receptor; vitamin C is a substrate/cofactor).
  • Some adaptive downregulation of SVCT1/SVCT2 transporters has been observed with chronic high intake, contributing to "rebound scurvy" after abrupt discontinuation from megadosing. Mitigation: taper down from chronic >1 g/d dosing over ~2 weeks rather than abrupt stop. Not relevant at 200-500 mg/d.
  • No cycling needed at maintenance doses. The 200-500 mg/d intake can run continuously.
  • For the training-adaptation concern: if running an endurance/conditioning block where mitochondrial adaptation is the goal, drop chronic vit C to ≤200 mg/d and avoid peri-workout dosing. Resume higher doses during rehab/cold-exposure/illness windows.
▸ Stacking deep dive

Synergistic with

  • vitamin E (α-tocopherol): Vitamin C regenerates the oxidized α-tocopheroxyl radical, allowing vitamin E to keep recycling at the lipid membrane interface. Classic combination. Caveat: 1 g vit C + 400 IU vit E is the Ristow 2009 / Paulsen 2014 stack that blunted training adaptation. Use this pair at lower doses (200-400 mg C + 100-200 IU E) or skip the combination in active endurance training.
  • iron (non-heme): 100 mg vit C with plant-iron meal doubles absorption. Time them together. Don't take with heme iron sources (no enhancement, may exaggerate iron overload risk).
  • glutathione / NAC: Vit C regenerates oxidized glutathione (GSSG → GSH), and GSH regenerates dehydroascorbate. Cooperative cycling. NAC provides cysteine precursor for GSH synthesis. Reasonable trio for antioxidant support — same caveat about peri-workout timing in endurance phases.
  • Collagen peptides / gelatin (Shaw protocol): 15 g collagen + 500 mg vitamin C 30-60 min pre-exercise — the strongest evidence-backed athletic-application stack for vit C. This is the targeted Dylan use case.
  • Bioflavonoids (citrus, rutin, quercetin): Synergistic antioxidant effect demonstrated in cell + animal models; modest human translation. Whole-food sources cover this naturally.
  • Zinc: Common cold lozenges combine zinc + vit C with modest additive duration-reduction effect.
  • Vitamin D3: No direct mechanistic synergy but co-supplementation is the standard "immune stack" — both improve respiratory infection resilience independently.

Avoid stacking with

  • Vitamin E at high dose during endurance training adaptation — see training-blunting evidence above.
  • Chemotherapy agents — vitamin C may interfere with some chemotherapy via antioxidant mechanism. Coordinate with oncology if relevant.
  • Methotrexate — theoretical interaction via acidified urine reducing renal clearance; clinically minor.
  • Iron supplements + meals high in non-heme iron + chronic vit C in hemochromatosis carrier — cumulative iron load risk.

Neutral / safe co-administration

  • All of Dylan's V4 stack (creatine, omega-3, magnesium glycinate, D3/K2, zinc, methylated B-complex, ashwagandha, rhodiola, L-theanine, glycine, taurine, NAC, citicoline, curcumin, beta-alanine, collagen peptides) — no problematic interactions with 200-500 mg/d vit C. Many are positively complementary.
  • Modafinil — neutral (vit C does not affect modafinil CYP3A4/amide hydrolysis kinetics meaningfully).
  • Caffeine — neutral.
  • Most peptides — neutral.
▸ Drug interactions deep dive
  • No significant CYP enzyme effects at supplementation doses.
  • Renal clearance: Vitamin C is renally cleared; severe renal impairment requires dose adjustment (rarely relevant in healthy adults). End-stage renal disease patients on dialysis lose vitamin C across the dialyzer and often require modest supplementation (75-100 mg/d).
  • Aspirin: High-dose aspirin reduces leukocyte ascorbate. Aspirin users may benefit from 100-200 mg/d vit C; chronic aspirin not relevant for Dylan.
  • Oral contraceptives: Reduce plasma ascorbate ~20-30% via altered binding/clearance. Adding 100-200 mg/d covers this for women on combined OCPs.
  • Iron-chelating drugs (deferoxamine, deferasirox): Co-administration of vitamin C with deferoxamine has been associated with cardiotoxicity in iron-overload patients. Avoid high-dose vit C in patients on iron chelation therapy.
  • Warfarin: High-dose vit C (>3 g/d) may reduce warfarin efficacy in case reports; clinically minor at typical doses.
  • Statins: No clinically significant interaction.
  • Antacids: Sodium-bicarbonate antacids reduce ascorbic acid absorption modestly via stomach pH; not clinically meaningful at typical doses.
  • Acetaminophen: Theoretical reduced sulfation of acetaminophen at very high vit C; not clinically significant.
  • Indinavir (HIV protease inhibitor): Vit C may reduce indinavir levels — not Dylan-relevant.
▸ Pharmacogenomics
  • SLC23A1 (SVCT1) variants: Affect intestinal absorption. Variants associated with lower plasma ascorbate. No actionable clinical recommendation yet but a genuine source of inter-individual variability — some people require higher intake to achieve the same plasma level.
  • SLC23A2 (SVCT2) variants: Affect cellular uptake, especially in immune cells and CNS. Polymorphisms associated with gastric cancer, oral cancer, and possibly preterm birth in observational studies. Practical translation thin.
  • GSTM1 / GSTT1 null genotype: Reduces glutathione-mediated regeneration of vitamin C; may explain why some users feel benefit from vit C + NAC combination more than others.
  • HFE C282Y / H63D (hemochromatosis): Highly relevant — confirmed homozygotes/compound heterozygotes should avoid >RDA chronic vit C. Heterozygotes are intermediate risk. Dylan should check this in 23andMe raw data.
  • G6PD deficiency variants: As above — relevant only for IV megadose use, not oral supplementation. Check on 23andMe.
  • GLO (gulonolactone oxidase) pseudogene: All humans have it — primates lost GLO function ~40 million years ago, which is why we require dietary vit C. Not a polymorphism affecting clinical decisions; just an evolutionary footnote.
  • COMT Val158Met: Indirectly relevant via catecholamine metabolism; not a vit C-specific PGx hit.

For Dylan: check HFE, G6PD, and SLC23A1/2 in 23andMe raw data via Promethease when results land. The most consequential is HFE status — if positive for hemochromatosis variant, dose ceiling drops to ≤100 mg/d and timing relative to iron meals changes.

▸ Sourcing deep dive
Form Vendor Cost Bioavailability Notes
Ascorbic acid (plain) NOW Foods, Nutricost, BulkSupplements $5-15 / 250 g powder; $8-15 / 250 ct 1000 mg tabs Standard reference (75% at 200 mg, falling at higher doses) Cheapest, mildly acidic, fine on full stomach. Pill or powder.
Sodium ascorbate (buffered) NOW, Pure Encapsulations $10-20 / 250 g powder Same as ascorbic acid Gentler on stomach; adds ~130 mg sodium per 1 g vit C (rarely clinically relevant).
Calcium ascorbate (Ester-C) American Health, NutraBio $15-25 / 100 ct 500 mg tabs Comparable, slightly slower absorption Marketed as "gentler"; modest evidence for slightly higher leukocyte retention. Premium price not strongly justified.
Magnesium ascorbate KAL, Pure Encapsulations Similar Comparable Useful if also stacking magnesium.
Liposomal vitamin C LivOn Labs (Lypo-Spheric), Quicksilver Scientific, Aurora Nutrascience $30-50 / 30 packets (1 g each) ~1.4× AUC vs plain at 4 g dose (Davis 2016 PMID 27375360); vendor claims of "90% BA" not supported by independent data Useful for high-dose immune/IV-substitute use case (cold, post-illness, oncology adjunct under MD supervision). Overpriced for daily 200-500 mg dosing.
Whole-food vitamin C (camu camu, acerola, amla) Multiple $20-40 / 60 ct caps Comparable; bioflavonoid co-content is the selling point More expensive per mg vit C than synthetic. Synthetic ascorbic acid is chemically identical to natural — the whole-food marketing is mostly about bioflavonoid co-factors.
Time-release ascorbic acid Nature Made, Solgar $10-20 / 100 ct 500-1000 mg Smooths plasma curve over ~8 h, raises overall AUC modestly Useful for hitting plasma saturation without GI burden.
Multivitamin-embedded vit C Various Variable Standard Most multis contain 60-200 mg — covers RDA without separate supplement. Check Dylan's V4 multivitamin if any.

For Dylan:

  • Daily baseline (200-500 mg/d): plain ascorbic acid tabs (NOW Foods 1000 mg tab cut in half = ~$0.04/dose) or sodium ascorbate powder (50 cents per month at 250 mg/d).
  • Shaw collagen protocol: dissolve 500 mg ascorbic acid powder into a serving of his collagen peptides + 8 oz water + a splash of OJ (vitamin C co-factor amplification + palatability), 45 min pre-BJJ.
  • Cold-season / camp window: add a second 500 mg dose mid-day.
  • Acute illness: keep 1 g chewable tabs in supplement drawer; dose 500 mg q6h for duration.
  • Skip liposomal — overpriced for daily use, no advantage at 200-500 mg dose range.
▸ Biomarkers to track (deep)

Baseline (before adding any supplementation)

  • Plasma ascorbate (less commonly run; ~40-90 µmol/L normal; <11 µmol/L is deficient). Most useful baseline marker if Dylan wants direct status data.
  • Ferritin + TIBC + transferrin saturation — confirm no iron overload before regular vit C with iron-containing meals.
  • hs-CRP — inflammation baseline. Vit C may reduce CRP modestly at chronic 500 mg/d.
  • CBC — baseline before any IV use (G6PD relevance if hemolysis ever suspected).
  • Comprehensive metabolic panel (creatinine, BUN) — confirm normal renal function (already in his June 2026 bloodwork).
  • Vitamin D 25(OH)D — co-immune marker (already in plan).
  • Diet log (3-day) — calculate baseline dietary vit C intake. If already >300 mg/d from food, supplementation is moot.

During use

  • No routine monitoring needed at 200-500 mg/d.
  • If running 1+ g/d chronically: annual ferritin (iron overload screen), annual urinary oxalate if any stone history.

Post-cycle / discontinuation

  • Not applicable at maintenance dose. If tapering off chronic megadose (>2 g/d for >3 months), do so over 1-2 weeks to avoid "rebound" hypoascorbatemia from SVCT1/2 downregulation.

MMA-specific (Dylan)

  • Subjective tendon/joint comfort tracking during Shaw-protocol windows (1-10 daily VAS for wrist, elbow, finger, knee, ankle — wherever current load is concentrated).
  • URTI episode frequency + duration before/during camps to validate Hemilä-cohort relevance n=1.
▸ Controversies / open debates Live debate

1. "Does supplementation matter at all if diet is good?"

  • Conservative view (most academic nutritionists): No. RDA is achievable from food, and supplementation beyond food intake shows minimal hard-endpoint benefit in healthy young adults.
  • Linus Pauling Institute view: Yes — they argue for 200 mg/d minimum based on Levine 1996 pharmacokinetics (the dose that saturates tissue/immune cells).
  • Practical reconciliation: For someone with reliably high fruit/vegetable intake, supplementation adds little. For training athletes with variable intake during camps or travel, a 200-500 mg/d insurance policy is cheap and safe.

2. "Mega-dose IV oncology — promising or fringe?"

  • Pauling/Cameron 1970s observational data was eventually contradicted by Mayo Clinic trials. Modern interest centers on the pro-oxidant mechanism at millimolar concentrations (paradoxically generating H2O2 selectively cytotoxic to some cancer cells).
  • Multiple small Phase I/II trials show feasibility + tolerability but no convincing survival benefit as monotherapy or adjuvant.
  • Not standard of care. Worth knowing about; not Dylan-relevant.

3. "Training adaptation blunting — overblown?"

  • Ristow 2009 + Paulsen 2014 are real and replicable at 1 g/d + vit E + endurance training.
  • Some studies (Higashida 2011, Yfanti 2010) show preserved adaptation — likely depends on training intensity, baseline antioxidant status, and exact dose/timing.
  • Practical conclusion: doses ≤500 mg/d not timed peri-workout are essentially risk-free; chronic 1+ g/d with vit E during endurance adaptation phases is plausibly counterproductive. Most non-elite athletes don't need to worry about this; elite endurance specialists do.

4. "Sepsis controversy — what happened?"

  • Marik's 2017 retrospective ("HAT therapy") suggested 87% mortality reduction in sepsis with vit C + thiamine + hydrocortisone. The biggest "too good to be true" result in critical care of the decade.
  • Subsequent VITAMINS, ACTS, and most damningly LOVIT (NEJM 2022, n=872 randomized) failed to replicate. LOVIT showed a mortality increase trend (44.5% vs 38.5%, HR 1.21).
  • Current status: vitamin C is not recommended for sepsis. The episode is a useful case study in the value of large pre-registered RCTs over enthusiastic observational signals.

5. "Is synthetic ascorbic acid as good as 'natural' (acerola, camu camu)?"

  • Chemically identical molecule. Synthetic ascorbic acid bioequivalence to whole-food sources confirmed in multiple PK studies.
  • Whole-food sources carry bioflavonoids and other antioxidants as part of the matrix — these have independent benefit but are not "vitamin C."
  • Marketing claim that whole-food vit C is "absorbed better" or "more bioavailable" is not supported.

6. "Should we be taking it pro-actively for cancer prevention?"

  • Epidemiology suggests dietary vit C intake (from fruits/vegetables) correlates with reduced GI cancer risk — but confounded by overall diet quality.
  • Supplementation RCTs (Physicians' Health Study II, Women's Health Study) showed no cancer-prevention benefit.
  • Diet > supplementation for cancer prevention.

7. "Liposomal — game-changer or marketing?"

  • Davis 2016 (PMID 27375360, n=11) showed liposomal AUC ~1.4× plain ascorbate at 4 g dose. Real but modest.
  • Vendor claims of "90% bioavailability" or "as effective as IV" are not supported by published data.
  • Practical use case: worth the premium price only for high-dose home protocols where IV isn't available (e.g., supportive care during illness, oncology adjunct under MD oversight). Not worth it for daily 200-500 mg.
▸ Verdict change log
  • 2026-05-14 — Graduated to thorough research pass. Verdict: OPTIONAL-ADD / HIGH confidence. Two confirmed use cases for Dylan: (1) Shaw protocol (500 mg pre-rehab + 15 g collagen) for tendon/ligament load — directly leverages V4 collagen peptides line; (2) 200-500 mg/d daily insurance with bump to 500 mg twice daily during MMA camps / cold exposure / acute illness. Outside those windows, food sources suffice. Action: add 250 mg ascorbic acid daily to V4; deploy Shaw protocol on heavy MMA training days; bump dose during camps + illness windows. Hemilä Cochrane 2013 athlete subgroup data (~50% URTI reduction) is the most relevant supplementation signal for this archetype.
  • 2026-05-13 — Initial medium pass verdict: OPTIONAL-ADD / HIGH confidence. Conservative starting position based on community-data block plus general nutritional knowledge.
▸ Open questions / gaps Open
  1. Dylan's HFE / G6PD / SLC23A1-2 PGx status — awaiting 23andMe June 2026. Most consequential for hemochromatosis risk (would drop ceiling to ≤100 mg/d) and G6PD (irrelevant for oral but relevant if IV is ever considered).
  2. Baseline plasma ascorbate — not currently in his June 2026 bloodwork panel. Worth adding if he wants to validate that food intake alone covers the saturation threshold.
  3. Quantified URTI episode rate during MMA camps — n=1 validation of Hemilä athlete data. Could be tracked alongside ring-health Oura/HR data.
  4. Shaw protocol n=1 efficacy — subjective tendon/joint comfort tracking during loaded rehab/training windows. The 3-month RFD signal (Praet 2021) would require structured measurement (e.g., countermovement jump RFD on force plate) to verify.
  5. Buffered vs plain ascorbic acid GI tolerance at 500 mg twice daily during camps — minor empirical optimization.
  6. Interaction with peri-workout antioxidant load — Dylan's V4 stack includes NAC (600 mg) and curcumin and other antioxidants. The cumulative "antioxidant cocktail" peri-workout concern is theoretical at his per-compound doses but worth noting as a research gap for the broader stack design.

References

Levine et al. 1996 PNAS — Vitamin C pharmacokinetics in healthy volunteers (PMID 8623000)

pubmed.ncbi.nlm.nih.gov · 1996

foundational pharmacokinetic paper establishing saturation kinetics, 200 mg single-dose bioavailability, and the basis for the 200 mg/d Linus Pauling Institute recommendation.

View Study

Hemilä & Chalker 2013 Cochrane — Vitamin C for preventing and treating the common cold (PMID 23440782)

pubmed.ncbi.nlm.nih.gov · 2013

definitive systematic review; 8% adult / 14% pediatric duration reduction with regular supplementation; ~50% incidence reduction in athletes/cold-exposed subgroup (5 trials, n=598).

View Study

Shaw et al. 2017 Am J Clin Nutr — Vitamin C-enriched gelatin + collagen synthesis (PMID 27852613)

pubmed.ncbi.nlm.nih.gov · 2017

the foundational athletic-application paper; 15 g gelatin + vit C pre-exercise doubled P1NP at 4 hr.

View Study

Lis & Baar 2019 Int J Sport Nutr Exerc Metab — Different vitamin C-enriched collagen derivatives on collagen synthesis (PMID 30859848)

pubmed.ncbi.nlm.nih.gov · 2019

confirmed both gelatin and hydrolyzed collagen + vit C work equivalently.

View Study

Praet et al. 2021 — Collagen + vitamin C × 3 months improves lower-limb rate of force development (PMID 34808597)

pubmed.ncbi.nlm.nih.gov · 2021

longest-duration outcome study supporting Shaw protocol's functional translation.

View Study

Linus Pauling Institute Vitamin C monograph (Oregon State)

lpi.oregonstate.edu

comprehensive evidence summary with the institute's 200 mg/d recommendation.

View Source

NIH Office of Dietary Supplements — Vitamin C Fact Sheet for Health Professionals

ods.od.nih.gov

authoritative US government summary.

View Source

LOVIT trial — Lamontagne et al. 2022 NEJM — Intravenous vitamin C in adults with sepsis in the ICU

nejm.org · 2022

the trial that ended the vit C in sepsis enthusiasm.

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…